<DOC>
	<DOCNO>NCT01192113</DOCNO>
	<brief_summary>This open-label , randomize , multi-center clinical trial evaluate safety efficacy peripheral neuropathy patient treat Mecobalamin Injection</brief_summary>
	<brief_title>Safety Efficacy Mecobalamin Injection Peripheral Neuropathies Patients ( Study JGAZSY091109 )</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<criteria>Inclusion criterion : 1 . Clinical diagnosis diabetes induce peripheral neuropathy , peripheral neuropathy ( Idiopathic , nutritional metabolic nature entrapment neuropathy ) . 2 . Significant spontaneous pain / numbness symptom neuropathy . TSS ( Total Symptom Score ) &gt; =7.5 . 3 . Participation clinical trial voluntarily sign informed consent form Exclusion criterion : 1 . Pregnancy , preparation pregnancy breastfeed woman 2 . Peripheral neuropathy cause drug , poisoning , cancer genetic 3 . Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) : 2.0 time upper limit normal ; Creatinine ( Cr ) 1.5 time upper limit normal . 4 . Serious organ disease serious primary disease merger , mentally ill , poorly control hypertension ( blood pressure 150/100 mmHg use antihypertensive drug ) 5 . Diagnosis patient diabetic peripheral neuropathy , diabetes ketosis , ketoacidosis severe infection within past two week 6 . Bleeding bleed tendency 2 month 7 . Have allergy 8 . Noncompliance meet 9 . Participation clinical trial last 3 month 10 . Participant unsuitable participate test investigator consider</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Mecobalamin</keyword>
	<keyword>peripheral neuropathy</keyword>
	<keyword>diabetic neuropathy</keyword>
</DOC>